AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04643067 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is the comparative arm.
Study NCT05710783 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AVX-COVID/12
Description: Single dose IM administration of a Recombinant Newcastle Disease Virus Vectored Vaccine for SARS-CoV-2
Study NCT05710783 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAdOx-1-S[recombinant]
Description: Single dose IM administration of ChAdOx1 nCOV-19 (Astra-Zeneca) adenovirus-vectored vaccine
Study NCT06249360 — intervention group
Intervention type: OTHER
Intervention: Veins with reflux
Description: This group included patients who used only recipient veins with reflux
Study NCT06249360 — intervention group
Intervention type: OTHER
Intervention: Reflux-free recipient veins
Description: This group included patients who utilized only reflux-free recipient veins
Study NCT06057727 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-visit patient text messaging
Description: Patients will be sent text message reminders 3 days and 24 hours prior to their scheduled primary care visit. The messages will inform the patient that a flu shot has been reserved for them at their upcoming appointment and encouraging the patient to ask their provider about receiving the vaccine.
Study NCT06057727 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Default pended order
Description: A default pended order for the flu vaccine will be pended to the patient's upcoming primary care encounter and will be visible to the provider during the visit encounter. Clinical staff will have the option of signing the order or dismissing it if they deem it inappropriate for a given patient.
Study NCT06057727 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monthly peer comparison feedback
Description: Each month, clinicians will be sent an email containing what percent of their eligible patients received the flu vaccine and how that compares to other peer clinicians in the intervention.
Study NCT06057727 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High risk bidirectional pre-visit text messaging
Description: High risk patients randomized to receive the high risk intensification nudge will receive a bidirectional text messaging component prior to their visit. This intervention will query the patient about common questions or concerns about receiving the flu vaccine. If the patient responds, it will provide additional educational materials based on the patient's specific concern(s).
Study NCT05410002 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Supplement: N-111
Description: Dietary supplement N-111
Study NCT05410002 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dietary placebo
Study NCT05754203 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Super-hyperfractionation Pulse Radiotherapy
Description: Radiotherapy design: a single dose of 0.5Gy, 16 consecutive pulses with an interval of 3 minutes (0.5Gy \* 16F), total dose DT: 8Gy; Immunotherapy: PD-1/PD-L1 monoclonal antibodies conforming to CSCO guidelines for lung cancer indications, including Carrilizumab, Tirelizumab, Teripril, Paborizumab, etc., conventional therapeutic dose, Q3W, until progression or the investigator judges that there is no longer clinical benefit or intolerable side effects.
Study NCT06651099 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mhealth application
Description: Individuals enrolled in the mhealth intervention will receive tailored content will include exercises focused on mobility, flexibility, core stabilization, and strengthening. Additionally, the mobile application will provide educational material on pain and health, covering topics such as the neurophysiology of pain, the multidimensional nature of low back pain, myths and facts about the condition, the importance of sleep, and stress management, which will include relaxation techniques and mindfulness. All content will be evidence-based, using clinical guidelines, systematic reviews and other high-quality studies to support inclusion in the mobile application. The intervention will be supervised by a physiotherapist, remotely via messaging or telephone calls.
Study NCT06651099 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional exercise therapy
Description: Participants in this intervention will receive a printed booklet containing a description and recommendations for carrying out an exercise program at home, which will be characterized by general exercises (such as strengthening, mobilization). The intervention will be supervised by a physiotherapist, remotely via messaging or telephone calls.
Study NCT06601894 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Platelets count
Description: the study include will take medical investigation data for all sickle cell patients.
Study NCT06589726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive a single oral dose of placebo matched to enpatoran in either of treatment period 1, 2, 3 and 4.
Study NCT06341283 — intervention group
Intervention type: DRUG
Intervention: Abemaciclib and Letrozole/Anastrozole
Description: Take the treatment with Abemaciclib and Letrozole/Anastrozole at the same time.
Study NCT06341283 — intervention group
Intervention type: DRUG
Intervention: Letrozole or Anastrozole
Description: Take the treatment with Letrozole or Anastrozole.
Study NCT06341283 — intervention group
Intervention type: DRUG
Intervention: Abemaciclib and Fulvestrant
Description: Take the treatment with Abemaciclib and Fulvestrant at the same time.
Study NCT06341283 — intervention group
Intervention type: DRUG
Intervention: Fulvestrant
Description: Take the treatment with Fulvestrant only.
Study NCT06494956 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implant device
Description: A subcutaneous tunnel was established under general anesthesia, the electrode was connected to the stimulator, and the pulse generator was implanted in the skull.
Study NCT06174701 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving Therapy (PST)
Description: PST intervention in the form of one-on-one coaching in preparation for surgery and post-operative care. This coaching consists of educating and guiding the patient in developing problem-solving skills. Please refer to the PST Handbook for further detail on the therapy sessions.
Study NCT04794998 — intervention group
Intervention type: DRUG
Intervention: Recommended treatment schedule
Description: Relatively selective Cox-2 inhibitors, Corticosteroids (Dexamethasone), Anticoagulants (LMW heparin), Gentle Oxygen therapy
Study NCT04794998 — intervention group
Intervention type: DRUG
Intervention: Control treatment schedule
Description: Treatment regimens different from the recommended one according to family phisicians personal practice.
Study NCT06091033 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fermented rice
Description: 1,000 mg of black rice (Oryza Sativa L.) extract fermented with Lactobacillus for 8 weeks
Study NCT06091033 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1,000 mg of a placebo for 8 weeks
Study NCT06403722 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Standard of care
Description: No intervention. Clinical evolution was recorded, looking for perinatal complications.
Study NCT05427916 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Avance Solo
Description: Avance® Solo will include the collective description for a complete device capable of delivering negative pressure to the incision site and managing exudate generated by the incision.
Study NCT05427916 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optifoam
Description: Optifoam is a silicone backed foam that is conformable, with a border that is waterproof, flexible and breathable for increased comfort, with a wear time of up to seven days. It is a standard of care product that is given to patients for surgical wounds.
Study NCT05415787 — intervention group
Intervention type: OTHER
Intervention: Blood sample
Description: 2 tubes Cell free DNA are taken during a blood sample already planned in the patient's care.
Study NCT05415787 — intervention group
Intervention type: OTHER
Intervention: Urine sample
Description: Urine sample is taken during the consultation carried out for the patient's care
Study NCT04386889 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Vasculitis In SLE
Description: 20 SLE female Egyptian patients, among them we are going to study the vasculitic pattern incidence.
Study NCT05983393 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: Erector spinae plane block was performed
Study NCT05983393 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Erector spinae plane block was not applied.
Study NCT03877822 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Habitual activity
Description: Two days of habitual physical activity, under normal free-living conditions
Study NCT03877822 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bed rest
Description: Two days of bed rest, to induce whole-body physical inactivity
Study NCT06576739 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Spinal Manipulation
Description: Daily administration of combination of vitamin B6,,vitamin B12, and folic acid
Study NCT06576739 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Manipulation
Description: Daily administration of combination of vitamin B6,,vitamin B12, and folic acid
Study NCT06364930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg Tab
Description: Dapagliflozin 10mg Tab QD for 60 months.
Study NCT06364930 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 10mg Tab
Description: Placebo 10mg Tab QD for 60 months.
Study NCT06478251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NW-301V
Description: TCR-T T cell targeting KRAS G12V mutation
Study NCT06478251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NW-301D
Description: TCR-T T cell targeting KRAS G12D mutation
Study NCT04677166 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy coupled with instillation
Description: Use of V.A.C. VeraFlo to treat skin grafts with NPWT coupled with instillation.
Study NCT04677166 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Negative Pressure Wound Therapy
Description: standard negative pressure wound therapy via V.A.C. Ulta device at 125mmHg suction.
Study NCT04894214 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Arterial blood gas (ABG)
Description: Arterial blood gasses will be drawn during baseline PCV, and every 15 minutes during FCV and VCV respectively. pO2 (mmHg), pCO2 (mmHg) and pH will be recorded.
Study NCT04894214 — intervention group
Intervention type: OTHER
Intervention: Recording of hemodynamic monitoring
Description: Hemodynamic parameters (invasive arterial blood pressure (mmHg) and heart rate (beats per minute)) will be recorded every 5 minutes.
Study NCT04894214 — intervention group
Intervention type: OTHER
Intervention: Recording of respiratory monitoring
Description: Tidal volume (ml), respiratory rate (breaths per minute), minute volume (l/min), dynamic compliance (ml/cmH2O), resistance (cmH2O/l/min), plateau pressure (cmH2O), mean airway pressure (cmH2O), positive end-expiratory pressure (cmH2O), peak inspiratory pressure (cmH2O) and fraction of inspired oxygen will be recorded every 5 minutes.
Study NCT04722848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib + Blinatumomab
Description: Patients aged 18-65 will receive Ponatinib at the dose of 45 mg/day for the first 22 days and then will reduce the dose to 30 mg (depending on the morphologic and molecular response), whereas patients older than 65 years will start Ponatinib at 30 mg/day, in order to avoid TAEs. Patients will continue treatment with Ponatinib up to day 70 (10 weeks of treatment), except for disease progression, intolerable toxicity, or withdrawal from study. Thereafter:~* Patients will receive Blinatumomab (minimum 2 cycles, up to a maximum of 5).~* Patients not achieving a CHR after 2 cycles of Blinatumomab will go off-study. After the 2 cycles of Blinatumomab patients aged 18-65 will be stratified for transplant allocation
Study NCT04722848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy + Imatinib
Description: patients aged 18-65 will receive chemotherapeutic scheme combined with Imatinib. Elderly patients will receive Imatinib plus mild chemotherapy.
Study NCT06589726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Participants will receive a single oral dose of moxifloxacin tablet (Treatment B) in either of treatment period 1, 2, 3 and 4.
Study NCT04890613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-5461
Description: 150 mg sterile lyophilized powder containing 1% sucrose
Study NCT06589726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enpatoran low dose
Description: Participants will receive a single oral low dose of enpatoran tablet (Treatment C) in either of treatment period 1, 2, 3 and 4.
Study NCT06589726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enpatoran high dose
Description: Participants will receive a single oral high dose of enpatoran tablet (Treatment D) in either of treatment period 1, 2, 3 and 4.
Study NCT05035498 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: A maintenance dose of phenylephrine (0.625 μg/kg/min) infusion simultaneous with subarachnoid block
Study NCT05035498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: A maintenance dose of norepinephrine (0.05 μg/kg/min) infusion simultaneous with subarachnoid block
Study NCT05523492 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered Cognitive Behavioural Therapy
Description: All clients will receive the Culturally Enhanced Wellbeing Course. The Course was originally developed at Macquarie University in Australia and was then culturally enhanced by the Online Therapy Unit in Saskatchewan Canada. The course is a trans-diagnostic Internet-delivered cognitive behaviour therapy intervention targeting symptoms of depression and anxiety. It comprises 5 online lessons targeting: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure; and 5) relapse prevention. Materials are presented in a didactic (i.e., text-based with visual images) and case-enhanced learning format (i.e., educational stories demonstrate the application of skills) and include homework activities. Lessons are released gradually in order over 8 weeks. Therapists will spend \~15 mins. per week/per client offering support via emails and or phone calls.
Study NCT04579861 — intervention group
Intervention type: OTHER
Intervention: Prospective data collection following gynaecological oncology surgery
Description: Prospective data collection and entry on database following gynaecological oncology surgery
Study NCT06356740 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: blood test to assess :~* human leukocyte antigen (HLA)-B\*5701 status to identify risk of allergy or hypersensitivity to abacavir (the study treatment)~* IFN-signature ans IFN-alpha dosage~* human immunodeficiency virus (HIV), hepatitis B virus (HBV) and Hepatitis C virus (HCV) serologies~* Human chorionic gonadotropin (βHCG)~* HERVs dosage A biological collection will also be created. The total volume of blood collected specifically for the research for the entire duration of the study is 62.5 millilitre (mL) maximum.
Study NCT06356740 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample
Description: blood test to assess :~* human leukocyte antigen (HLA)-B\*5701 status to identify risk of allergy or hypersensitivity to abacavir (the study treatment)~* IFN-signature ans IFN-alpha dosage~* human immunodeficiency virus (HIV), hepatitis B virus (HBV) and Hepatitis C virus (HCV) serologies~* Human chorionic gonadotropin (βHCG)~* HERVs dosage A biological collection will also be created. The total volume of blood collected specifically for the research for the entire duration of the study is 62.5 millilitre (mL) maximum.
Study NCT06356740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment :Abacavir 600 mg/lamivudine 300 mg
Description: Patients randomised to the experimental arm will be required to take 1 tablet (600 mg lamivudine and 300 mg abacavir) once daily for 6 months in addition to their usual treatment.
Study NCT06356740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lupus Impact Tracker questionnaire
Description: Patients will be asked to complete the Lupus Impact Tracker questionnaire at visit V1 (randomisation visit), visit 3 (at 6 months of treatment) and visit 4 (12 months after visit 1).
Study NCT06356740 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lupus Impact Tracker questionnaire
Description: Patients will be asked to complete the Lupus Impact Tracker questionnaire at visit V1 (randomisation visit), visit 3 (at 6 months of treatment) and visit 4 (12 months after visit 1).
Study NCT05056714 — intervention group
Intervention type: OTHER
Intervention: Questionaries
Description: The patient will answer several questionaries
Study NCT06203431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ET-26
Description: freeze-dried powder injection，The initial dose is 0.8 mg/kg, with an additional 50% starting dose if needed. single dose, Infusion time was 60s ± 5s.
Study NCT06203431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etomidate Injectable Emulsion
Description: lipid emulsion ，The initial dose is 0.3 mg/kg, with an additional 50% starting dose if needed.single dose, Infusion time was 60s ± 5s.
Study NCT04987593 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Once a day daily intake of probiotics, at least for 28 consecutive days before giving birth and for at least 28 consecutive days after giving birth
Study NCT06487949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valsartan-amlodipine 80/5 mg FDC
Description: fix dose combination of valsartan 80 mg and Amlodipine 5 mg given as single pill
Study NCT06487949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valsartan 80 mg and amlodipine 5 mg as free combination
Description: Free combination of valsartan 80 mg and amlodipine 5 mg given separately
Study NCT05371704 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamin Supplementation
Description: Participants will supplement daily with an over-the-counter oral multivitamin pill
Study NCT05371704 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dietary Replication
Description: Patients will record their dietary intake in an estimated food diary during the first trial. During the second trial, participants will be asked to replicate their diet from the first trial
Study NCT05371704 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Replication
Description: Patients will record their dietary intake in an estimated food diary during the first trial. During the second trial, participants will be asked to replicate their diet from the first trial
Study NCT04899037 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study of participants that either choose or not choose to utilize an OID. This is not an intervention prescribed study, however, participants may choose uptake of standard of care intervention and obtain and utilize an OID. An OID is an FDA-approved device commonly recommended to patients with conductive, mixed, or singled-sided hearing loss. There is no experimental intervention evaluated in this study.
Study NCT05520775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide (subcutaneous)
Study NCT05520775 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham/placebo
Description: Sham subcutaneous injection
Study NCT05059132 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-rehabilitation
Description: The tele-rehabilitation intervention will include education, inspiratory muscle training, and behavioral support to promote walking.
Study NCT05059132 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education only
Description: The education only arm will receive information on the importance of general exercise following lung cancer treatment.
Study NCT04983732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FL-101-Intravenous
Description: 150 mg administered via the IV route
Study NCT04983732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FL-101-Subcutaneous
Description: 150 mg administered via the SC route
Study NCT06403501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clascoterone
Description: Clascoterone Cream 1% (Winlevi) is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.
Study NCT06403501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle cream
Description: Vehicle cream manufactured to mimic look and feel of Clascoterone Cream 1% but without the active ingredient.
Study NCT06236997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Etoposide 100mg/m2 day1-3+carboplatin AUC 5 day 1(EC) combined with Adebrelimab（ PD-L1 inhibitor）1200mg day1 Q3w for 2 cycles, and the efficacy is evaluated 3 weeks after the treatment. If the efficacy evaluation is SD/PR/CR, concurrent radiotherapy(45Gy /3Gy/qd/3w) with EC(2 cycles) + Adebrelimab will be initiated. After concurrent chemoradiotherapy+ Adebrelimab, Adebrelimab was maintained until PD or intolerance or for at most 2 years.